Literature DB >> 24532518

Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Yun Hwa Kim1, Ji Young Hwang, Hye Min Shim, Eunsil Lee, Songyong Park, Hosun Park.   

Abstract

PURPOSE: To evaluate a recently marketed commercial glycoprotein enzyme-linked immunosorbent assay (gpEIA) kit, the VaccZyme™ VZV gpEIA, for measuring the immunity of varicella-vaccinated children.
MATERIALS AND METHODS: We investigated the accuracy and reproducibility of the VaccZyme™ VZV gpEIA kit for the detection of antibodies to VZV. We also examined the sensitivity, specificity, and correlation between antibody titers calculated with gpEIA versus fluorescent antibody to membrane antigen (FAMA) by using sera of 349 children, ranging from 1 to 6 years old.
RESULTS: VaccZyme™ VZV gpEIA gave precise and reproducible intra- and inter-assay results. FAMA and gpEIA titers showed a linear correlation (Pearson correlation coefficient=0.987). The sensitivity and specificity of the VaccZyme™ gpEIA was 31.4% and 100%, respectively, when the guidelines of the gpEIA (<100 mIU/mL) and FAMA 1:4 were adopted as cutoff values. However, the maximum sensitivity and specificity were 88.9% and 95.1%, respectively, with the highest correlation (κ=0.840), if the cutoff values were set with gpEIA at 49.7 mIU/mL and FAMA 1:16.
CONCLUSION: These results demonstrate that the VaccZyme™ VZV gpEIA kit gave precise and reproducible data for measuring antibody titer after varicella vaccination. The results also showed that the antibody titer calculated with the VaccZyme™ gpEIA kit strongly correlated with the FAMA titer. However, cutoff values should be re-optimized for the evaluation of vaccine immunity.

Entities:  

Keywords:  FAMA test; Varicella; gpEIA; immunogenicity; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24532518      PMCID: PMC3936636          DOI: 10.3349/ymj.2014.55.2.459

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  45 in total

1.  Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.

Authors:  C J White; B J Kuter; A Ngai; C S Hildebrand; K L Isganitis; C M Patterson; A Capra; W J Miller; D L Krah; P J Provost
Journal:  Pediatr Infect Dis J       Date:  1992-01       Impact factor: 2.129

2.  Seroprevalence rate after one dose of varicella vaccine in infants.

Authors:  So Hee Kim; Hoan Jong Lee; Su Eun Park; Sung Hee Oh; Seong Yeon Lee; Eun Hwa Choi
Journal:  J Infect       Date:  2010-04-07       Impact factor: 6.072

3.  Antibody assays for varicella-zoster virus: comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation.

Authors:  B Forghani; N J Schmidt; J Dennis
Journal:  J Clin Microbiol       Date:  1978-11       Impact factor: 5.948

Review 4.  Assays for antibodies to varicella-zoster virus.

Authors:  D L Krah
Journal:  Infect Dis Clin North Am       Date:  1996-09       Impact factor: 5.982

5.  Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies.

Authors:  P M Keller; K Lonergan; B J Neff; D A Morton; R W Ellis
Journal:  J Virol Methods       Date:  1986-09       Impact factor: 2.014

6.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

7.  Clinical reinfection with varicella-zoster virus.

Authors:  A A Gershon; S P Steinberg; L Gelb
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

8.  Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine.

Authors:  B Watson; R Gupta; T Randall; S Starr
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

9.  Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.

Authors:  Shu Li; Ivan S F Chan; Holly Matthews; Joseph F Heyse; Christina Y Chan; Barbara J Kuter; Karen M Kaplan; S J Rupert Vessey; Jerald C Sadoff
Journal:  Pediatr Infect Dis J       Date:  2002-04       Impact factor: 2.129

10.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02
View more
  8 in total

1.  Evaluation of a multiplex bead immunoassay for determination of immune status to varicella-zoster virus in medical center students and employees.

Authors:  Michael J Loeffelholz; Harry E Prince
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

2.  Enhanced Potency and Persistence of Immunity to Varicella-Zoster Virus Glycoprotein E in Mice by Addition of a Novel BC02 Compound Adjuvant.

Authors:  Junli Li; Lili Fu; Yang Yang; Guozhi Wang; Aihua Zhao
Journal:  Vaccines (Basel)       Date:  2022-03-29

Review 3.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

4.  Detection of antibodies to varicella-zoster virus in recipients of the varicella vaccine by using a luciferase immunoprecipitation system assay.

Authors:  Jeffrey I Cohen; Mir A Ali; Ahmad Bayat; Sharon P Steinberg; Hosun Park; Anne A Gershon; Peter D Burbelo
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

5.  Seroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test.

Authors:  S B Han; K R Kang; D H Huh; H C Lee; J H Kim; J H Kang; S H Ma
Journal:  Epidemiol Infect       Date:  2014-09-19       Impact factor: 2.451

6.  Calibration and Evaluation of Quantitative Antibody Titers for Varicella-Zoster Virus by Use of the BioPlex 2200.

Authors:  Elizabeth McLachlan; Heidi Scholz; Shelly Bolotin; Natasha S Crowcroft; Todd F Hatchette; Colleen Jackson; Alberto Severini
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

7.  The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Haedicke; M Quinlivan; S P Steinberg; A A Gershon; K E Brown; J Breuer
Journal:  Epidemiol Infect       Date:  2016-03-28       Impact factor: 2.451

8.  Cross-Sectional Study of Varicella Zoster Virus Immunity in Healthy Korean Children Assessed by Glycoprotein Enzyme-Linked Immunosorbent Assay and Fluorescent Antibody to Membrane Antigen Test.

Authors:  Yunhwa Kim; Ji-Young Hwang; Kyung-Min Lee; Eunsil Lee; Hosun Park
Journal:  Vaccines (Basel)       Date:  2021-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.